Nuravax and Institute for Molecular Medicine Announce Publication of Phase 1 Results for AV-1959R Amyloid-Beta Vaccine
Randomized, placebo-controlled study in 16 cognitively unimpaired participants met safety and immunogenicity objectives; all 12 vaccine recipients developed anti-Aβ antibodies after two priming doses Randomized, double-blind, placebo-controlled Phase 1 trial enrolled 16 cognitively...
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Cancele cuando quiera · 99 CA$/mes


